FROM GENETIC OBSERVATIONS TO FUNCTIONAL INSIG
Geneettisistä löydöksien translaatio potilaiden hoidoksi
Tilaisuuden ohjelma
MINERVA FOUNDATION SYMPOSIUM 2025 – program
Registration for the Symposium begins in August 2025.
For further information or questions regarding the Symposium, please contact Cia Olsson, cia.olsson@minervainstitute.fi.
Thursday 23 October 2025
13:00 Opening of the Symposium, Vesa Olkkonen, Minerva Foundation Institute for Medical Research
SESSION I – Steatotic liver disease – Leveraging genetics for therapeutic insights
13:05 Chairperson Hannele Yki-Järvinen, Minerva Foundation Institute for Medical Research
13:10-13:35 Panu Luukkonen, Minerva Foundation Institute for medical Research
Hepatic mitochondrial reductive stress – from genetics via bench to bedside
13:40-14:15 Russell Goodman, Harvard/Massachusetts General Hospital, USA
Reductive stress in steatotic liver disease – focus on GCKR
14:20-14:55 Shawn Burgess, UT Southwestern, USA
Intermediary metabolism in steatotic liver disease – focus on ACC
15:00-15:20 Sami Qadri, Minerva Foundation Institute for medical Research
Functional characterization of protective gene variants in steatotic liver disease
15:20-15:50 Coffee
SESSION II – Incretins – Bench to bedside
15:50 Chairperson Daniel Gordin, Minerva Foundation Institute for Medical Research
15:55-16:30 Petter Bjornstad, University of Washington, Seattle, USA
Incretins – Gut to brain and back
16:35-17:10 David Cherney, University of Toronto, Canada
Incretins in patients with type 1 diabetes
17:15-17:50 Ian de Boer, University of Washington, Seattle, USA
Incretins in the kidney guidelines 2027
18:00-19:30 Wine and snacks
Friday 24 October 2025
SESSION III – Bone and mineral metabolism, its genetic components and therapeutic approaches
8:30 Chairperson, Heikki Koistinen, Minerva Foundation Institute for Medical Research
8:35-9:10 Wim van Hul, University of Antwerp, Belgium
The road from the discovery of sclerostin mutations to clinical applications
9:15-9:50 Harald Jüppner, Massachusetts General Hospital, Harvard Medical School, Boston, USA
The clinical landscape of parathormone signaling
9:55-10:20 Outi Mäkitie, Folkhälsan, University of Helsinki and Helsinki University Hospital
Monogenic osteoporosis – lessons from rare phenotypes to population health problems
10:25-10:50 Heikki Koistinen, Minerva Foundation Institute for Medical Research
Kidney stone disease and genetics of hypercalciuria
10:50-11:20 Coffee
SESSION IV – Genetics and pharmacogenetics in personalized medicine
11:20 Chairperson Miina Ollikainen, Minerva Foundation Institute for Medical Research
11.25-12:00 Hanna Ollila, FIMM, University of Helsinki and Stanford University, CA, USA
Genetic and functional analysis of Raynaud’s syndrome implicates loci in vasculature and immunity
12:05-12:40 Adrian Krainer, Cold Spring Harbor Laboratory, NY, USA
Splicing defect as a cause of spinal muscular atrophy (SMA): Therapy with a splicing-correcting antisense oligonucleotide
12:40-13.30 Lunch
13.30:-13:55 Mikko Niemi, University of Helsinki
Pharmacogenetics in personalized medicine
14:00-1:25 Elisabeth Widen, FIMM, University of Helsinki
Inherited infertility – mapping loci associated with impaired female reproduction
14:30-15.30 PANEL DISCUSSION – Emerging new therapies: The path from innovation to cost-effective benefit to the patients
Moderator Sami Pakarinen, Helsinki University Hospital
Panelists Ian de Boer, Petter Bjornstad, Daniel Gordin, Harald Jüppner, Adrian Krainer and Wim van Hul
Closing of the Symposium